Frequently Asked Questions
The global emphysema market is projected to grow at a CAGR of 6.50% during the forecast period of 2022-2029.
Type (Centriacinar, Panacinar, Paraseptal, Others), Diagnosis (Imaging Test, Lab Test, Spirometry, Others), Complications (Chest Infections, Collapsed Lung (Pneumothorax), Heart Problems, Lungs Hole (bullae), Others), Treatment (Medication, Therapy, Surgery, Others), Route of Administration (Oral, Parenteral, Inhalation, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) are covered in this report.
The key opportunities of the Emphysema Market are Increased Incidences of Congestive Heart Failure.
The major players operating in the market are Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Intersect ENT, Inc (U.S.).
